NCT03684889View on ClinicalTrials.gov

CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 28, 2018

Primary Completion Date

February 8, 2021

Study Completion Date

December 31, 2036

Conditions
LeukemiaLymphoma
Interventions
BIOLOGICAL

SCRI-huCAR19v1

1:1 mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG

BIOLOGICAL

SCRI-huCAR19v2

Mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG

Trial Locations (2)

90027

Children's Hospital Los Angeles, Los Angeles

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
lead

Seattle Children's Hospital

OTHER